Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-04-10
2008-08-19
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S254000
Reexamination Certificate
active
07414068
ABSTRACT:
The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The compounds of the present invention can be used for protecting neuronal cells and brain damage; antioxidation; inhibiting NO generation; protecting heart; suppressing angiogenesis; protecting preserving organs such as kidney, heart and tissue, and protecting organs in major cardiovascular surgery.
REFERENCES:
patent: 5837702 (1998-11-01), Rovnyak et al.
patent: 6034256 (2000-03-01), Carter et al.
Mattson, M. P., et al., Calcium, Free Radicals, and Excitotoxic Neuronal Death in Primary Cell Culture,Methods in Cell Biology, vol. 46, pp. 187-216, (1995).
Zhang, Y., et al., “Basic FGF, NGF, and IGFs Protect Hippocampal and Cortical Neurons Against Iron-Induced Degeneration”,Journal of Cerebral Blood Flow and Metabolism, vol. 13, No. 3, pp. 378-388, (1993).
Okubo, S., et al., “Myocardial preconditioning: Basic concepts and potential mechanisms”,Molecular and Cellular Biochemistry, vol. 196, pp. 3-12, (1999).
Starkov, A.A., “‘Mild’ Uncoupling of Mitochondria”,Bioscience Reports, vol. 17, No. 3, pp. 273-279, (1997).
Skulachev, V.P., “Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants”,Quarterly Reviews of Biophysics, vol. 29, No. 2, pp. 169-202, (1996).
Grover, G.J., “Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion”,Can. J. Physiol. Pharmacol., vol. 75, pp. 309-315, (1997).
Lopaschuk, G.D., et al., “Manipulation of Energy Metabolism in the Heart”,Science&Medicine, pp. 42-51, (Nov./Dec. 1997).
Atwal, K.S., et al., “Cardioselective Anti-Ischemic ATP-Sensitive Potassium Channel Openers. 3. Structure-Activity Studies on Benzopyranyl Cyanoguanidines: Modification of the Cyanoguanidine Portion”,J. Med. Chem.vol. 38, No. 17, pp. 3236-3245, (1995).
Rovnyak, G.C., et al., “Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KATP) Openers. 5. Indentification of 4-(N-Aryl)-Substitiuted Benzopyran Derivatives with High Selectivity”,J. Med. Chem.vol. 40, No. 1, pp. 24-34, (1997).
Atwal, K.S., et al., “Treatment of Myocardial Ischemia with ATP-Sensitive Postassium Channel (KATP) Openers”,Current Pharmaceutical Design, vol. 2, No. 5, pp. 585-595, (1996).
Folkman, J., et al., “Angiogenic Factors”,Science, vol. 235, pp. 442-447, (1987).
Lee, A., et al., “Shark Cartilage Contains Inhibitors of Tumor Angiogenesis”,Science, Vo. 221, pp. 1185-1187, (1983).
Crum, R., et al., “A New Class of Steroids Inhibits Angiogensis in the Presence of Heparin or a Heparin Fragment”,Science, vol. 230, pp. 1375-1378, (1985).
Jurd, L., “New Anti-tumor Agents. 2. Benzopyranylamine Compounds”,J. Heterocyclic Chem., vol. 33, No. 6, pp. 1919-1925, (1996).
Gladstone, D.J., et al., “Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions”, Stroke, vol. 33, pp. 2123-2136, (2002).
Sziraki, I., et al., “Manganese: A Transition Metal Protects Nigrostriatal Neurons from Oxidative Stress in the Iron-Induced Animal Model of Parkinsonism”,Neuroscience, vol. 85, No. 4, pp. 1101-1111, (1998).
Goodman, Y., et al., “K+ channel openers protect hippocampal neurons against oxidative injury and amyloid β-peptide toxicity”, Brain Research, vol. 706, pp. 328-332, (1996).
McCord, J.M., “The Evolution of Free Radicals and Oxidative Stress”,The American Journal of Medicine, vol. 108, pp. 652-659, (2000).
Moreau, J., et al., “Central adenosine A2Areceptors: an overview”,Brain Research Reviews, vol. 31, pp. 65-82, (1999).
Loidl, C.F., et al., “Effects of hypothermia and gender on survival and behavior after perinatal asphyzia in rats”,Physiology&Behavior, vol. 68, pp. 263-269, (2000).
Naka, K., et al., “Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+-K+-ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes”,Diabetes Research and Clinical Practice, vol. 30, pp. 153-162, (1995).
Chambers, D.J., et al., “Developments in Cardioprotection: ‘Polarized’ Arrest as an Alternative to ‘Depolarized’ Arrest”,Ann. Thorac. Surg., vol. 68, pp. 1960-1966, (1999).
Folkman, J., et al., “Angiogensis”,The Journal of Biological Chemistry, vol. 267, No. 16, pp. 10931-10934, (1992).
Mazzon, E., et al., “GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation”,European Journal of Pharmacology, vol. 415, pp. 85-94, (2001).
Nieber, K., “Hypozia and Neuronal Function under in Vitro Conditions”,Pharmacol. Ther.vol. 82, No. 1, pp. 71-86, (1999).
Paschen, W., et al., “Comparison of In Vitro Ischemia-Induced Disturbances in Energy Metabolism and Protein Synthesis in the Hippocampus of Rats and Gerbils”,Journal of Neurochemistry, vol. 65, pp. 1692-1697, (1995).
Luhmann, H.J., “Ischemia and Lesion Induced Imbalances in Cortical Function”,Procgress in Neurobiology, vol. 48, pp. 131-166, (1996).
De Keyser, J., et al., “Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?”,Trends Neurosci., vol. 22, pp. 535-540, (1999).
Dirnagle, U., et al., “Pathobiology of ischaemic stroke: an integrated view”,Trends Neurosci.vol. 22, pp. 391-397, (1999).
Choi In-Young
Kim Nak-Jeong
Kim Sun-Ok
Lee Byung-Ho
Lee Dong-Ha
Chung Susannah
Dongbu Hannong Chemical Co. Ltd.
Goldberg Joshua B.
Harkins Tanya E.
Shameem Golam M. M.
LandOfFree
Benzopyran derivatives substituted with secondary amines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzopyran derivatives substituted with secondary amines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzopyran derivatives substituted with secondary amines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001664